Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In 1986, Kärre and colleagues reported that natural killer (NK) cells rejected an MHC class I-deficient tumor cell line (RMA-S) but they did not reject the same cell line if it expressed MHC class I (RMA). Based on this observation, they proposed the concept that NK cells provide immune surveillance for “missing self,” e.g., they eliminate cells that have lost class I MHC antigens. This seminal observation predicted the existence of inhibitory NK cell receptors for MHC class I. Here, we present evidence that NK cells are able to reject tumors expressing MHC class I if the tumor expresses a ligand for NKG2D. Mock-transfected RMA cells resulted in tumor formation. In contrast, when RMA cells were transfected with the retinoic acid early inducible gene-1 γ or δ (RAE-1), ligands for the activating receptor NKG2D, the tumors were rejected. The tumor rejection was mediated by NK cells, and not by CD1-restricted NK1.1 + T cells. No T cell-mediated immunological memory against the parental tumor was generated in the animals that had rejected the RAE-1 transfected tumors, which succumbed to rechallenge with the parental RMA tumor. Therefore, NK cells are able to reject a tumor expressing RAE-1 molecules, despite expression of self MHC class I on the tumor, demonstrating the potential for NK cells to participate in immunity against class I-bearing malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Cerwenka et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Self-citationBiology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., & Salazar-Mather, T. P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.189 · Cited by 2,113
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Self-citationCosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232
An Activating Immunoreceptor Complex Formed by NKG2D and DAP10
Wu, J., Song, Y., Bakker, A. B. H., Bauer, S., Spies, T., Lanier, L. L., & Phillips, J. H. (1999) · Science · doi:10.1126/science.285.5428.730 · Cited by 1,039
Self-citationBroad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB
Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., & Spies, T. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6879 · Cited by 1,028
Groh, V, Bahram, S., Bauer, S., Herman, A., Beauchamp, M., & Spies, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12445 · Cited by 1,017
Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R., & Spies, T. (2001) · Nature Immunology · doi:10.1038/85321 · Cited by 951
Research works printed but not linked: 2
- 10.1146/annurev.iy.10.040192.001201 · doi:10.1146/annurev.iy.10.040192.001201 · Paper page
- S Bahram Adv Immunol 76, 1–60 (2000).
Cited by
Items 101–200 of 691
NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases
Zompi, S., Hamerman, J. A., Ogasawara, K., Schweighoffer, E., Tybulewicz, V. L. J., Di Santo, J. P., Lanier, L. L., & Colucci, F. (2003) · Nature Immunology · doi:10.1038/ni930 · Cited by 189
Self-citationHeinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187
Variable receptors controlling activation and inhibition of NK cells
McQueen, K. L., & Parham, P. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00380-1 · Cited by 186
Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways
Coudert, J. D., Scarpellino, L., Gros, F., Vivier, E., & Held, W. (2008) · Blood · doi:10.1182/blood-2007-07-100057 · Cited by 185
Hayakawa, Y., Kelly, J. M., Westwood, J. A., Darcy, P. K., Diefenbach, A., Raulet, D., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5377 · Cited by 185
Two Human ULBP/RAET1 Molecules with Transmembrane Regions Are Ligands for NKG2D
Bacon, L., Eagle, R. A., Meyer, M., Easom, N., Young, N. T., & Trowsdale, J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1078 · Cited by 184
Deguine, J., Bréart, B., Lemaître, F., Santo, J. P. D., & Bousso, P. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.016 · Cited by 179
The DNA Damage Response Arouses the Immune System
Gasser, S., & Raulet, D. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4603 · Cited by 178
Release of MICB Molecules by Tumor Cells: Mechanism and Soluble MICB in Sera of Cancer Patients
Salih, H. R., Goehlsdorf, D., & Steinle, A. (2006) · Human Immunology · doi:10.1016/j.humimm.2006.02.008 · Cited by 178
Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902937809 · Cited by 175
Physical Activity and Cancer Prevention: Pathways and Targets for Intervention
Rogers, C. J., Colbert, L. H., Greiner, J. W., Perkins, S. N., & Hursting, S. D. (2008) · Sports Medicine · doi:10.2165/00007256-200838040-00002 · Cited by 170
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer
Smyth, M. J., Swann, J., Kelly, J. M., Cretney, E., Yokoyama, W. M., Diefenbach, A., Sayers, T. J., & Hayakawa, Y. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041522 · Cited by 169
Jinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168
NKG2D ligands: unconventional MHC class I‐like molecules exploited by viruses and cancer
Cerwenka, A., & Lanier, L. L. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00070.x · Cited by 167
Self-citationNKG2D Ligands in Tumor Immunity: Two Sides of a Coin
Zhang, J., Basher, F., & Wu, J. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00097 · Cited by 146
Leveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 166
Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy
Prajapati, K., Pérez, C., Plaza-Rojas, L., Burke, B., & Guevara-Patino, J. A. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.161 · Cited by 164
Bugide, S., Green, M. R., & Wajapeyee, N. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802691115 · Cited by 155
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
Regulation of ligands for the activating receptor NKG2D
Mistry, A. R., & O'Callaghan, C. A. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02652.x · Cited by 160
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
Koelwyn, G. J., Wennerberg, E., Demaria, S., & Jones, L. W. (2015) · PubMed · Cited by 162
von Strandmann, E. P., Hansen, H. P., Reiners, K. S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V. R., Draube, A., Reiser, M., Purr, I., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2177 · Cited by 157
Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells
Sun, B., Yang, D., Dai, H., Liu, X., Jia, R., Cui, X., Li, W., Cai, C., Xu, J., & Zhao, X. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0026 · Cited by 156
Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0167-1 · Cited by 152
Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells
Nausch, N., Galani, I. E., Schlecker, E., & Cerwenka, A. (2008) · Blood · doi:10.1182/blood-2008-03-143776 · Cited by 151
Self-citationAbsi, A. A., Wurzer, H., Guérin, C. L., Hoffmann, C., Moreau, F., Mao, X., Brown-Clay, J. D., Petrolli, R., Casellas, C. P., Dieterle, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0441 · Cited by 150
The role of the NKG2D receptor for tumor immunity
Coudert, J. D., & Held, W. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.008 · Cited by 150
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149
Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J.-M., Rousselot, P., Tamouza, R., Le Bouteiller, P., Mahon, F.-X., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.5108 · Cited by 148
de Kruijf, E. M., Sajet, A., van Nes, J. G. H., Putter, H., Smit, V. T. H. B. M., Eagle, R. A., Jafferji, I., Trowsdale, J., Liefers, G., van de Velde, C. J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-24 · Cited by 148
ULBP6/RAET1L is an additional human NKG2D ligand
Eagle, R. A., Traherne, J. A., Hair, J. R., Jafferji, I., & Trowsdale, J. (2009) · European Journal of Immunology · doi:10.1002/eji.200939502 · Cited by 148
Soluble NKG2D ligands: prevalence, release, and functional impact
Salih, H. R., Holdenrieder, S., & Steinle, A. (2008) · Frontiers in bioscience · doi:10.2741/2939 · Cited by 145
Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression
Song, H., Kim, J.-K., Cosman, D. J., & Choi, I. (2006) · Cellular Immunology · doi:10.1016/j.cellimm.2006.03.002 · Cited by 145
Lança, T., Correia, D. V., Moita, C. F., Raquel, H., Neves‐Costa, A., Ferreira, C., Ramalho, J. S., Barata, J. T., Moita, L. F., Gomes, A. Q., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237123 · Cited by 139
NKG2D in NK and T Cell-Mediated Immunity
Ogasawara, K., & Lanier, L. L. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-8786-4 · Cited by 138
Self-citationSuppression of tumor formation in lymph nodes by L-selectin–mediated natural killer cell recruitment
Chen, S., Kawashima, H., Lowe, J. B., Lanier, L. L., & Fukuda, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051473 · Cited by 114
Self-citationCerboni, C., Fionda, C., Soriani, A., Zingoni, A., Doria, M., Cippitelli, M., & Santoni, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00508 · Cited by 136
A basolateral sorting motif in the MICA cytoplasmic tail
Suemizu, H., Radosavljevic, M., Kimura, M., Sadahiro, S., Yoshimura, S., Bahram, S., & Inoko, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052701099 · Cited by 136
Girart, M. V., Fuertes, M. B., Domaica, C. I., Rossi, L. E., & Zwirner, N. W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3472 · Cited by 131
Genetics, genomics, and evolutionary biology of NKG 2D ligands
Carapito, R., & Bahram, S. (2015) · Immunological Reviews · doi:10.1111/imr.12328 · Cited by 130
Immune selective pressure and HLA class I antigen defects in malignant lesions
Chang, C., & Ferrone, S. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0183-1 · Cited by 129
Eleme, K., Taner, S. B., Önfelt, B., Collinson, L., McCann, F. E., Chalupny, N. J., Cosman, D. J., Hopkins, C. R., Magee, A. I., & Davis, D. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032194 · Cited by 129
Chang, C., Campoli, M. R., & Ferrone, S. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)93006-6 · Cited by 128
New prospects on the NKG2D/NKG2DL system for oncology
Ullrich, E., Koch, J., Cerwenka, A., & Steinle, A. (2013) · OncoImmunology · doi:10.4161/onci.26097 · Cited by 127
Self-citationPlatelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells
Maurer, S., Kropp, K. N., Klein, G., Steinle, A., Haen, S. P., Walz, J. S., Hinterleitner, C., Märklin, M., Kopp, H., & Salih, H. R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1364827 · Cited by 127
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
Liu, G., Lu, S., Wang, X., Page, S. T., Higano, C. S., Plymate, S. R., Greenberg, N. M., Sun, S., Li, Z., & Wu, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69369 · Cited by 127
IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism
Takaki, R., Hayakawa, Y., Nelson, A., Sivakumar, P. V., Hughes, S., Smyth, M. J., & Lanier, L. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2167 · Cited by 126
Self-citationFuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A., & Zwirner, N. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4606 · Cited by 105
Märten, A., von Lilienfeld‐Toal, M., Büchler, M. W., & Schmidt, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22186 · Cited by 125
Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis
Shaykhiev, R., & Bals, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0207096 · Cited by 126
The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia
Nückel, H., Switala, M., Sellmann, L., Horn, P. A., Dürig, J., Dührsen, U., Küppers, R., Grosse‐Wilde, H., & Rebmann, V. (2010) · Leukemia · doi:10.1038/leu.2010.74 · Cited by 122
Maleno, I., López‐Nevot, M. Á., Cabrera, T., Jose, S., & Garrido, F. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0296-0 · Cited by 122
Biology and clinical impact of human natural killer cells
Farag, S. S., VanDeusen, J. B., Fehniger, T. A., & Caligiuri, M. A. (2003) · International Journal of Hematology · doi:10.1007/bf02983234 · Cited by 121
Zafirova, B., Mandarić, S., Antulov, R., Krmpotić, A., Jonsson, H., Yokoyama, W. M., Jonjić, S., & Polić, B. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.017 · Cited by 120
Schwinn, N., Vokhminova, D., Sucker, A., Textor, S., Striegel, S., Moll, I., Nausch, N., Tuettenberg, J., Steinle, A., Cerwenka, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24098 · Cited by 118
Self-citationPark, Y. P., Choi, S.-C., Kiesler, P., Gil-Krzewska, A., Borrego, F., Weck, J., Krzewski, K., & Coligan, J. E. (2011) · Blood · doi:10.1182/blood-2011-04-346825 · Cited by 117
Signal Transduction in Natural Killer Cells
Macfarlane, A. W., & Campbell, K. S. (2005) · Current topics in microbiology and immunology · doi:10.1007/3-540-27743-9_2 · Cited by 119
Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
Valés-Gómez, M., Chisholm, S. E., Cassady-Cain, R. L., Roda-Navarro, P., & Reyburn, H. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2973 · Cited by 96
The NKG2D receptor: immunobiology and clinical implications
Burgess, S. J., Maasho, K., Masilamani, M., Narayanan, S., Borrego, F., & Coligan, J. E. (2007) · Immunologic Research · doi:10.1007/s12026-007-0060-9 · Cited by 114
Upshaw, J. L., & Leibson, P. J. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.001 · Cited by 114
Bedel, R., Thiery-Vuillemin, A., Grandclément, C., Balland, J., Rémy-Martin, J.-P., Kantelip, B. M., Pallandre, J., Pivot, X. B., Ferrand, C., Tiberghien, P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-09-4540 · Cited by 113
NK Cells and Cancer Immunoediting
Guillerey, C., & Smyth, M. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_446 · Cited by 112
Huenecke, S., Zimmermann, S. Y., Kloeß, S., Esser, R., Brinkmann, A., Tramsen, L., Koenig, M., Erben, S., Seidl, C., Tonn, T., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181bb46f7 · Cited by 111
Innate immune recognition by stimulatory immunoreceptors
Diefenbach, A., & Raulet, D. H. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00007-9 · Cited by 108
Intestinal inflammation and colorectal cancer: a double-edged sword?
Rizzo, A., Pallone, F., Monteleone, G., & Fantini, M. C. (2011) · PubMed · doi:10.3748/wjg.v17.i26.3092 · Cited by 107
Mechanisms of Immune Evasion by Gliomas
Rolle, C. E., Sengupta, S., & Lesniak, M. S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3146-6_5 · Cited by 107
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Sutherland, C. L., Rabinovich, B., Chalupny, N. J., Brawand, P., Miller, R., & Cosman, D. (2006) · Blood · doi:10.1182/blood-2005-11-011320 · Cited by 106
NKG2D and cytotoxic effector function in tumor immune surveillance
Hayakawa, Y., & Smyth, M. J. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.03.005 · Cited by 106
Immunosurveillance and immunotherapy of tumors by innate immune cells
Iannello, A., Thompson, T. W., Ardolino, M., Marcus, A., & Raulet, D. H. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.11.001 · Cited by 105
Ebihara, T., Azuma, M., Oshiumi, H., Kasamatsu, J., Iwabuchi, K., Matsumoto, K., Saito, H., Taniguchi, T., Matsumoto, M., & Seya, T. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20091573 · Cited by 105
CD8 T Cell Help for Innate Antitumor Immunity
Shanker, A., Verdeil, G., Buferne, M., Inderberg-Suso, E.-M., Puthier, D., Joly, F., Nguyen, C., Leserman, L., Auphan-Anezin, N., & Schmitt-Verhulst, A.-M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6651 · Cited by 104
McGilvray, R. W., Eagle, R. A., Rolland, P., Jafferji, I., Trowsdale, J., & Durrant, L. G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25156 · Cited by 104
Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis
Molfetta, R., Quatrini, L., Santoni, A., & Paolini, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081677 · Cited by 103
IFN-Dependent Down-Regulation of the NKG2D Ligand H60 on Tumors
Bui, J. D., Carayannopoulos, L. N., Lanier, L. L., Yokoyama, W. M., & Schreiber, R. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.905 · Cited by 101
Self-citationBeyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells
Eagle, R. A., Jafferji, I., & Barrow, A. D. (2009) · Current Immunology Reviews · doi:10.2174/157339509787314369 · Cited by 101
Wesselkamper, S. C., Eppert, B. L., Motz, G. T., Lau, G. W., Hassett, D. J., & Borchers, M. T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5481 · Cited by 101
Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., & Rossi, L. E. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.01.013 · Cited by 100
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Xiao, T., Lee, J., Gauntner, T. D., Velegraki, M., Lathia, J. D., & Li, Z. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00680-z · Cited by 101
Crosby, E. J., Goldschmidt, M. H., Wherry, E. J., & Scott, P. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003970 · Cited by 94
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg, K., Bryceson, Y. T., Carlsten, M., Andersson, S., Björklund, A. T., Björkström, N. K., Baumann, B. C., Fauriat, C., Alici, E., Dilber, M. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0492-7 · Cited by 98
Non‐classical MHC class I molecules on intestinal epithelial cells: mediators of mucosal crosstalk
Shao, L., Kamalu, O., & Mayer, L. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00295.x · Cited by 98
Hervieu, A., Rébé, C., Végran, F., Chalmin, F., Bruchard, M., Vabres, P., Apétoh, L., Ghiringhelli, F., & Mignot, G. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.273 · Cited by 98
Lundqvist, A., McCoy, J. P., Samsel, L., & Childs, R. W. (2006) · Blood · doi:10.1182/blood-2006-05-024315 · Cited by 97
Ni, J., Hölsken, O., Miller, M., Hammer, Q., Luetke-Eversloh, M. V., Romagnani, C., & Cerwenka, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1219009 · Cited by 97
Self-citationMICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer
Cho, H., Chung, J., Kim, S., Braunschweig, T. A., Kang, T. H., Kim, J., Chung, E. J., Hewitt, S. M., & Kim, J.-H. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-957 · Cited by 95
Armeanu, S., Krusch, M., Baltz, K. M., Weiß, T. S., Smirnow, I., Steinle, A., Lauer, U. M., Bitzer, M., & Salih, H. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4744 · Cited by 95
Adams, E. J., Juo, Z. S., Venook, R., Boulanger, M. J., Arase, H., Lanier, L. L., & García, K. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703735104 · Cited by 95
Self-citationThe role of natural killer cells in tumor control—effectors and regulators of adaptive immunity
Wallace, M. E., & Smyth, M. J. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0195-x · Cited by 95
The Natural Killer Cell – Friend or Foe in Autoimmune Disease?
Flodström‐Tullberg, M., Shi, F., Sarvetnick, N., & Ljunggren, H. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01084.x · Cited by 94
The NKG2D receptor and its ligands–recognition beyond the “missing self”?
Watzl, C. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(02)00057-6 · Cited by 100
DAP12: an adapter protein with dual functionality
Takaki, R., Watson, S. R., & Lanier, L. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00466.x · Cited by 93
Self-citationMcCann, F. E., Eissmann, P., Önfelt, B., Leung, R., & Davis, D. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3418 · Cited by 90
Endothelial cells express NKG2D ligands and desensitize antitumor NK responses
Thompson, T. W., Kim, A. B., Li, P. J., Wang, J., Jackson, B. T., Huang, K. T. H., Zhang, L., & Raulet, D. H. (2017) · eLife · doi:10.7554/elife.30881 · Cited by 90
Öberg, L., Johansson, S., Michaëlsson, J., Tomasello, E., Vivier, É., Kärre, K., & Höglund, P. (2004) · European Journal of Immunology · doi:10.1002/eji.200424913 · Cited by 90
Sconocchia, G., Lau, M., Provenzano, M., Rezvani, K., Wongsena, W., Fujiwara, H., Hensel, N. F., Melenhorst, J. J., Li, J., Ferrone, S., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0479 · Cited by 90
NK cells: innate immunity against hematological malignancies?
Costello, R. T., Fauriat, C., Sivori, S., Marcenaro, E., & Olive, D. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.04.005 · Cited by 89
Sun, S., Feng, Y., Xu, D., Zheng, H., & Li, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188700 · Cited by 87
Ogasawara, K., Yoshinaga, S. K., & Lanier, L. L. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3676 · Cited by 87
Self-citationJinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
Proteasome Regulation of ULBP1 Transcription
Butler, J. E., Moore, M. B., Presnell, S. R., Chan, H.-W., Chalupny, N. J., & Lutz, C. T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801214 · Cited by 69
Metadata
- Authors
- Cerwenka, A., Baron, J. L., & Lanier, L. L.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-09-18
- Volume
- 98
- Issue
- 20
- Pages
- 11521-11526
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC58762
- OpenAlex
- W2056645320
- Cited by
- 606
- References
- 34
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 20 · 2021: 15 · 2020: 24 · 2019: 17 · 2018: 15 · 2017: 26 · 2016: 14 · 2015: 22 · 2014: 27 · 2013: 25 · 2012: 24
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- National Institutes of Health
- National Cancer Institute (CA89189, R01CA089189)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Keywords
- Rae1, NKG2D, natural killer cells, MHC class I, tumor rejection, missing self, NK cell receptors, immune surveillance, NK1.1+ T cells, tumor rechallenge
- MeSH terms
- Animals, B-Lymphocytes, Female, Immunoglobulin Fc Fragments, Immunologic Memory, Killer Cells, Natural, Lymphocyte Depletion, Lymphoma, Major Histocompatibility Complex, Membrane Proteins, Mice, Inbred C57BL, Recombinant Fusion Proteins, Transfection, Tumor Cells, Cultured, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.